https://doi.org/10.17795/ijcp-3755

Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens

authors:

avatar Soudeh Ghafouri-Fard ORCID 1 , * , avatar Mahnaz Seifi-Alan 1 , avatar Roshanak Shamsi 1 , avatar Ali Esfandiary 1

Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Iranian Journal of Cancer Prevention: Vol.8, issue 5; e3755
published online: October 27, 2015
article type: Review Article
received: August 4, 2015
revised: August 29, 2015
accepted: September 22, 2015

how to cite: Ghafouri-Fard S, Seifi-Alan M, Shamsi R, Esfandiary A. Immunotherapy in Multiple Myeloma Using Cancer-Testis Antigens. Int J Cancer Manag. 2015;8(5):e3755. https://doi.org/10.17795/ijcp-3755.

Abstract

Context:

Multiple myeloma (MM) is a B-cell malignancy characterized by monoclonal expansion of abnormal plasma cells in the bone marrow. It accounts for 10% of hematological malignancies. Although patients respond to a wide range of anticancer modalities, relapse occurs in a significant number of the cases. Immunotherapeutic approaches have been evolved to tackle this problem. Cancer-testis antigens CTAs as a group of tumor-associated antigens are appropriate targets for cancer immunotherapy as they have restricted expression pattern in normal tissues except for testis which is an immune-privileged site. Expression of these antigens has been assessed in different malignancies including MM.

Evidence Acquisition:

We performed a computerized search of the MEDLINE/PubMed databases with key words: multiple myeloma, cancer-testis antigen, and cancer stem cell and immunotherapy.

Results:

Several CTAs including NY-ESO-1, MAGE and GAGE family have been shown to be expressed in MM patients. Cellular and humoral immune responses against these antigens have been detected in MM patients.

Conclusions:

The frequent and high expression level of CTAs in MM patients shows that these antigens can be applied as cancer biomarkers as well as targets for immunotherapy in these patients.

1. Context

Multiple myeloma (MM) is the second most frequent hematological malignancy accounting for 10% of all hematological malignancies and 1% of all cancers (1). The main characteristic of this B-cell malignancy is the monoclonal expansion of abnormal plasma cells in the bone marrow which results in heterogeneous manifestations of the disorder including bone pain and fractures, symptoms of inadequate hematopoiesis, hypercalcemia, hyperviscosity, renal failure, infections and peripheral neuropathy (1, 2). Several chromosomal, genetic and epigenetic events have been known to contribute to plasma cell transformation as well as disease progression (3). The most significant epigenetic changes detected during the transformation of monoclonal gammopathy of undetermined significance (MGUS) to myeloma are global hypomethylation and gene-specific hypermethylation (3).

A wide range of anticancer modalities such as conventional cytotoxic chemotherapy, corticosteroids, radiation therapy, in addition to an increasing number of drugs with novel mechanisms of action such as lenalidomide and bortezomib are being used in MM patients. However, relapse and disease resistance occur in a considerable subset of patients (4, 5). This problem necessitates a search for novel modalities with the ability to target the population of cells which are responsible for relapse. Immunotherapy as a new strategy to tackle the problem of relapse has gained attention from researchers. In this field, cancer-testis antigens (CTAs) have been identified as appropriate targets for immunotherapy of cancer.

2. Evidence Acquisition

In order to collect data about expression of CTAs in MM, we performed a computerized search of the MEDLINE/PubMed databases with the key words: multiple myeloma, cancer-testis antigen, cancer stem cells and immunotherapy.

2.1. Cancer Stem Cells (CSCs) in MM

MM is one of the first tumors assumed to arise from proliferation of a rare population of CSCs (6). Evidences supporting the presence of CSCs in MM came from studies which showed that myeloma plasma cells are functionally competent and able to make monoclonal immunoglobulin. In addition, it has been shown that most of such cells are quiescent which implies that tumor growth is limited to a specialized cell population (4). CSCs have been shown to have some biological features of normal adult stem cells such as self-renewal and expression of specific cell markers (7). MM stem cells have the ability of self-renewal in addition to producing differentiated effectors (specifically plasma cells) (4). Another characteristic of normal stem cells is resistance to toxic injury, which is believed to be shared by myeloma stem cells. The evidences for such idea have come from the results of studies showing the persistent risk of relapse among MM patients after treatment with standard therapies. Moreover, in vitro studies have shown that MM CSCs are relatively resistant even to novel agents compared with the myeloma plasma cells (4). The exact phenotypic characteristics of MM CSCs have not been clarified yet. However, it has been demonstrated that these cells do not express CD138. Such circulating clonotypic B-cell populations are responsible for the relative drug resistance in MM which is mediated by processes that guard normal stem cells against toxic injury. These processes include drug efflux and intracellular drug detoxification (8). Some CTAs have been shown to be preferentially expressed in CSCs derived from lung, colon and breast adenocarcinomas as well as glioma cell lines (9). However, the expression pattern of CTAs in MM CSCs remains to be elucidated.

2.2. Immunotherapy in MM

The role of immune system in the prevention of cancers and specifically hematological malignancies has been demonstrated by increased incidence of such malignancies in immunesuppressed patients. However, various tumor escape mechanisms contribute to the failure of immune system in such an attempt. Among them are abnormal number and function of dendritic cells (DCs), loss of expression of major histocompatibility complex (MHC), expansion of regulatory T cells (Treg), decreased T-cell cytotoxic activity and responsiveness to IL-2, as well as impairment of B-cell immunity which have been demonstrated in MM (10-12). In addition, a role for myeloid-derived suppressor cells in the pathogenesis of myeloma has been highlighted in recent years (13). Importantly, adaptive immune system has been shown to have a role in the control of MM given that donor-derived T cells participate in the effectiveness of allogeneic stem cell transplantation and when infused into MM patients can induce remission in relapsed patients (14). Consequently, diverse immunotherapeutic approaches such as monoclonal antibodies, idiotype or peptide vaccines, DC vaccines, adoptive T-cells immunotherapy as well as strategies to interrupt negative regulation of immune system have been developed and used in MM patients (15). Such approaches provide new tools for removal of residual disease after treatment (16). Although the ability of immunotherapeutic approaches to eliminate MM CSCs has not been evaluated yet, evidences suggest small fractions of MM cells which escape the action of chemotherapy and are invisible by conventional techniques can be destroyed by cytotoxic T lymphocytes (CTLs) (17). CTAs are appropriate targets for active-specific immunotherapy which has the important characteristic of inducing highly effective antitumor T lymphocytes and memory functions. As shown in MM patients, infusion of donor lymphocytes in relapsed and refractory patients could induce long-term remission (18). Consequently, researches are focused on feasibility and efficacy of CTA-based immunotherapeutic approaches in MM patients.

3. Results

3.1. Cancer-Testis Antigen (CTA) Expression in MM

CTAs are a group of tumor associated antigens (TAAs) with restricted expression in normal somatic tissues, with expression in gametogenic tissues as well as a wide variety of tumors (19-24). Such expression pattern has provided them with properties to be used as cancer biomarkers (25) as well as targets for cancer immunotherapy because of the immune-privileged status of the testis (26, 27). However, some of genes previously attributed to this family have been shown to be expressed in normal somatic tissues at a level comparable to gametogenic tissues which necessitate reevaluation of the expression of so called genes in normal tissues (28). According to their expression pattern, CTAs can be classified to three categories of testis-restricted, testis/brain-restricted and testis-selective (29). Assessment of CTAs expression in different tissues is important in estimation of probability of immunotherapy side-effects (16). Although the function of all CTAs has not been defined yet, some of them are shown to have relevant functions in the process of tumorigenesis. This is especially an important criterion for a TAA being used in immunotherapy to prevent alternative clonal progression. Other critical characteristics of appropriate targets for immunotherapy are restricted expression in normal tissues to reduce toxicity when targeted and expression in a large population of patients to increase applicability (15). Both of these properties have been demonstrated for CTAs. Expression of CTAs in spermatocytes and their function in meiosis imply that their aberrant expressions in cancer cells may cause abnormal chromosome segregation and aneuploidy, rationalizing their significance in the process of tumorigenesis (17). CTA expression in tumor cells has been assumed to be regulated by epigenetic mechanisms, namely demethylation (21). The absence or low expression of CTAs in differentiated somatic tissues implies that their expression in tumor tissue might be confined to cells that maintain stem cell properties i.e. CSCs (17). The expression of various CTAs has been assessed in MM samples and cell lines. These antigens have been proposed as applicable prognostic markers in newly diagnosed MM patients as well as relapse patients (16). In addition, longitudinal studies have indicated a strong correlation between CTA expression and the clinical course of MM in such a way that only a small percentage of patients in complete remission have been shown to express CTAs. On the contrary, half of the patients in partial remission have been shown to express CTAs (14). Table 1 summarizes a list of CTA genes whose expression has been identified in MM patients.

Table 1.

Cancer-Testis Antigens With Expression in Multiple Myeloma (MM) Patients

Gene Expression Pattern Among Normal TissuesChromosomal LocationPhysiological FunctionExpression Frequency in MM PatientsReference
ADAM2Testis-selective8p11.2Sperm-egg membrane bindingAnalyzed only in MM cell lines(30, 31)
AKAP4Testis-selectiveXp11.2Signal transduction via targeting cyclic adenosine monophosphate-dependent protein kinase-A42%(32, 33)
BAGETestis-selective21p11.1-27%(34, 35)
BRDTTestis-selective1p22.1May have a role in spermatogenesis2%(36)
CCDC36Testis/brain-restricted3p21.31-56%(16)
CDCA1(NUF2)Testis-selective1q23Kinetochore-microtubule interactions, chromosome alignment and segregation58%(16, 37)
CEP290Testis-selective12q21.32Microtubule organization and ciliogenesis68%(16, 38)
CEP55Testis-selective10q23.33Has an important role in cytokinesis77%(16, 39)
CPXCR1Testis-restrictedXq21.3-51%(16)
CRISP2Testis-selective6p21 - qterRegulate ion channel activity6%(36)
CT45Not availableXq26.3Modulation of cell morphology, cell adherence and cell motility6 - 40%(36)
CTAGE1Testis/brain-restricted18p11.2-56 - 92%(16, 40, 41)
CTAGE5Testis-selective14q13.3-95%(16)
CTTNNA2Testis/brain-restricted2p12 - p11.1Regulator for the stability of synaptic contacts26.5-61%(16, 42)
DDX43Testis-selective6q12 - q13-24%(36)
DSCR8Testis-selective21q22.2-10%(36)
FAM133ATestis/brain-restrictedXq21.32-79 - 86%(16)
FATE1Testis-selectiveXq28-39%(16)
IGSF11Testis-selective3q13.32Cell adhesion60%(16)
JARID1BTestis-selective1q32.1A strong transcriptional repressor82%(16)
KM-HN-1Not available4q35.1-15 - 56%(36)
LDHCTestis-selective11p15.3 - p15.5A metabolic catalyst11%(30, 36)
LIP1Testis-selective21q11.2-Analyzed only in MM cell lines(30)
MAGE-A1Testis-restrictedXq28MAGE-A proteins interact with p53 proteins and may block the association of p53 with its cognate sites in chromatin.16 - 22%(16, 35)
MAGE-B2Testis-restrictedXp21.3Activate RING E3 ubiquitin ligases28 - 47%(16)
MAGE-C1Testis-restrictedXq26Activate RING E3 ubiquitin ligases61 - 73%(16)
MAGE-C2Testis/brain-restrictedXq27Activate RING E3 ubiquitin ligases9.5 - 29%(16)
MORCTestis-selective3q13Spermatogenesis57%(36)
NOL4Testis-selective18q12-54%(16, 43)
NY-ESO-1Testis-restrictedXq28-7 - 36%(31, 35)
PAGE1Not availableXp11.23-3%(36)
PAGE2Testis-restrictedXp11.21-6%(16)
PASD1Testis-restrictedXq28Transcription factor87%(44, 45)
PBKTestis-selective8p21.2Protein kinase, control of cell proliferation94%(16)
PRAMETestis-selective22q11.22-23%(34)
PTPN20ATestis-selective10q11.22Tyrosine phosphatase25%(43)
ROPN1Testis-restricted3q21.1Testis specific anchoring protein44%(46)
SPACA3Testis-selective17q11.2Binding of spermatozoa to the oocytes during fertilization33 - 55%(36)
SPAG9Testis-selective17q21.33A scaffolding protein100%(16)
SPANXCTestis-restrictedXq27.1-0.1 - 5%(16, 36)
SPO11Testis-selective20q13.2 - q13.3Homologous recombination during meiosis0.2 - 27%(16, 36)
SSX1Testis-restrictedXp11.23Transcriptional regulator30%(16)
SYCP1Testis-selective1p12 - p13Assembly of the synaptonemal complexes10%(47)
TEX14testis-restricted17q22Intercellular bridges in germ cells7%(16, 43)
TDRD110q25.3-0.5%(36)
TSPY1Testis-restrictedYp11.2Control of cell cycle progression, cell proliferation and tumorigenesis10%(16)
XAGE1Testis-selectiveXp11.22-1 - 20%(16, 36)
XAGE3Testis-selectiveXp11-4 - 12.5%(36)

3.1.1. CTAG2 (LAGE1)

In an expression study of CTAs in MM patients, it has been demonstrated to be the second most frequently expressed CTA after MAGE-C1/CT7 (34). Its expression has been shown to result in recognition of tumor cells by LAGE specific autologous CTLs (48). Its expression in relapsed MM cases has been shown to be associated with shorter progression free survival (16). It is among the genes whose expressions in MM patients have been shown to be correlated with resistance to proteasome inhibitor bortezomib (40). Its amino acid sequence is highly similar to NY-ESO-1 (34). It has been shown to be expressed in half of stage III myelomas and plasma cell leukemia (35) as well as about half of MM patients in another independent study (34). Its expression has been frequently detected in a selection of MM patients, despite the notably lower expression of its close homologue NY-ESO-1. It has been suggested that because of the high sequence homology, LAGE-1 may also induce an immune response against NY-ESO-1. Moreover, the concomitant expression of LAGE-1 and NY-ESO-1 has been detected in 23% of the advanced stage MM patients (36).

3.1.2. GAGE Family

In total, expression GAGE family genes have been detected in one-third of MM patients. Their expression has been identified as an independent prognostic factor in MM patients (34). GAGE-4 and GAGE-8 are testis/brain-restricted antigens with higher expression frequency in relapse MM patients than in newly diagnosed ones (16). GAGE-1 and GAGE-12 have been shown to be over-expressed in a group of patients in which genes involved in cell cycle and proliferation were over-expressed, which verifies the association between CTA genes and prognosis (42).

3.1.3. MAGE Family

MAGE family members locate on the X chromosome and share a 200 amino acid common domain, named MHD (MAGE Homology Domain) (49). The expression of MAGE family members in tumor cells seems to participate in the malignant phenotype and poor response to treatment modalities (50). They may participate in tumor transformation or in some features of tumor progression for instance in tumor metastasis (51). A previous study has shown that about one-third of MM samples express at least 1 of the MAGE-A genes, and about two-third express at least 1 of the MAGE-type genes (35). Most of these genes have testis-restricted expression pattern. However, some of them have a less restricted expression pattern in normal tissues. As in most studies the expression pattern of these genes has been evaluated altogether. We will discuss them in a separate part.

3.1.3.1. MAGE-A Genes

MAGE-A1 and MAGE-A2 expressions have been shown in new cases as well as relapse cases of MM with comparable frequencies (16). MAGE-A3 gene has been shown to be involved in the survival of myeloma cells, reducing drug induced apoptosis (52). MAGE-A3 has been previously suggested as a gatekeeper CT gene in solid tumors (53). However, a more recent study in MM patients has indicated that MAGE-C1/CT7 strongly predict simultaneous expression of other CTAs, even of MAGE-A3 (14). MAGE-A3 has been shown to be expressed in more than half of MM patients with bone marrow plasma cell infiltration > 10% (14). MAGE-A6 and MAGE-A9 expressions in newly diagnosed MM patients have been associated with shorter progression free survival and shorter overall survival respectively. MAGE-A9 has been expressed in relapse patients as well (16). MAGE-A2, MAGE-A4, MAGE-A5, MAGE-A6, MAGE-A8 and MAGE-12 have been shown by microarray analysis to be expressed in MM patient samples and cell lines but not in MGUS. However, MAGE-A4 and MAGE-A8 are expressed in a subset of normal peripheral blood memory B cells (36).

3.1.3.2. MAGE-B Genes

MAGE-B2 has been among the most frequent testis-restricted CTAs in both newly diagnosed and relapse MM patients with higher expression frequency in new cases. However, it has been proved to be expressed in a subset of normal plasma cells. MAGE-B1 and MAGE-B4 have also been demonstrated to be expressed in both patient sets (16).

3.1.3.3. MAGE-C Genes

MAGE-C1 gene is located in the region Xq26-27. Immunofluorescence staining has shown its protein in the cytoplasm as well as in the cell nucleus. In addition, MAGE-C1/CT7 has physical interaction with NY-ESO-1 protein, implying that the coordinated expression of these two genes is a frequent happening in many types of tumors, such as MM (54). It has been among the most common testis-restricted CTAs in both newly diagnosed and relapsed MM patients with expression in a small percentage of normal plasma cells (16). The expression of its protein has been demonstrated in most MM, medullary plasmacytoma, and extramedullary plasmacytoma samples (55, 56). Furthermore, its expression on the cell surface has been shown in the CAG myeloma cell line and one case of plasmacytoma (55). As MAGE-C1/CT7 expression seems to arise early in the course of disease, it may have a function in the early stages of MM and may participate in plasma cell proliferation (34). The involvement of MAGE-C1/CT7 in survival of malignant MM cells has been demonstrated in two independent studies aimed at MAGE-C1/CT7 silencing. Both studies have shown that MAGE-C1/CT7 expression in MM decreases drug induced apoptosis (52, 57). MAGE-C1/CT7 expression has been frequently detected in osteolytic lesions of MM patients with higher expression frequency in patients with advanced stage of disease and with a chromosomal deletion of 17p13 (p53). In addition, an association has been found between the percentage of MAGE-C1/CT7 expressing myeloma cells and higher proliferative rate (58). MAGE-C1/CT7 expression has been shown to be high post therapy and in the relapse cases (16). Notably, it has been shown that if a patient expressed a MAGE-C1/CT7 at least once, the likelihood for its expression in relapse is close to 100%, a finding that is important for selection of MAGE-C1/CT7 as a target for immunotherapy. As it has been proved to be present even in remission phase, it is an appropriate target for immunotherapy in minimal residual disease (14). The correlation of MAGE-C1/CT7 expression with disease stage, patient prognosis and survival has been assessed in various studies. For instance, higher expression of MAGE-C1/CT7 has been observed in samples of MM stage III, compared to individuals with MGUS or lower stages suggesting its relation to disease progression in myeloma (34, 56). Another study has shown that MAGE-C1/CT7 is more expressed in patients with newly diagnosed MM compared with patients with MGUS and its expression is associated with shorter survival (36). In addition, sub cellular localization of MAGE-C1/CT7 has been shown to be correlated with prognosis in such a way that its pure cytoplasmic expression was associated with a better prognosis than combined nuclear-cytoplasmic or nuclear expression only (44). Furthermore, MAGE-C1/CT7 expression in malignant plasma cells from bone marrow has a prognostic value in early recurrence and worse overall survival after allogeneic hematopoietic stem cells transplant (alloSCT) and correlates with disease burden after treatment (14). In another study, its expression has been identified as the only independent prognostic factor in non-transplanted patients (34). Its expression has been demonstrated to be more frequent in newly diagnosed MM cases than in relapse cases (16). MAGE-C1/CT7-specific T lymphocytes have been identified in MM patients implying the suitability of this antigen for immunotherapeutic approaches (46, 59, 60). MAGE-C1 has been proposed as a gatekeeper gene for expression of other CTAs (14).

MAGE-C2 is a testis/brain-restricted antigen with higher expression frequency in newly diagnosed than relapse MM patients (16). Its expression has been frequently detected in osteolytic lesions of MM patients (58). It has been demonstrated to be expressed in about two-third of MM patients with bone marrow plasma cell infiltration > 10% (14). The high expression frequency of MAGE-C2 in MM implies that this antigen might represent a potential target for cancer vaccines especially when considering the results of previous studies which showed its capability to elicit spontaneous humoral as well as CD8 + T cell responses in patients with MAGE-C2 expressing solid tumor (30).

3.1.4. NY-ESO-1

It encodes the most immunogenic CTA. It has been proved to be expressed in about one-third of stage III myelomas and plasma cell leukemias (35) as well as the same percentage of total MM samples (34). In addition, its expression has been seen in an extramedullary plasmocytoma patient who also showed a strong immune response against NY-ESO-1 (30). The increased expression of NY-ESO-1 has been demonstrated in MM patients with cytogenetic abnormality (CA) compared to patients with normal cytogenetics. In addition, high NY-ESO-1 expression has been seen in relapsing MM particularly those with CA. Spontaneous NY-ESO-1-specific antibodies have been detected in one-third of NY-ESO-1 expression patients especially in CA patients. Furthermore, spontaneous NY-ESO-1-specific T cells have been found in the peripheral blood of NY-ESO-1 expressing patients and these cells were able to kill primary MM cells after expansion (61).

3.1.5. ROPN1

It is a testis-restricted antigen which is shown to be expressed in MM cell lines as well as about half of the MM primary samples. The immunogenicity of ROPN1 has been verified by the occurrence of specific antibodies in patients’ sera. Its expression at the cell surface of MM plasma cells makes it a promising target for MM immunotherapy. In addition, HLA class I-restricted cytotoxic lymphocytes have been generated with ability to kill autologous MM cells (62).

3.1.6. SSLP1

It is a novel CTA whose expression has been demonstrated in most MM cell lines at RNA and protein levels while it was not expressed in normal bone marrow. In addition, it has been proved to be expressed in a high percentage of MM patients at least once during the course of their disease as well as in considerable percentage of newly diagnosed patients. Of note, its expression was associated with adverse cytogenetics, negative prognostic factors as well as a reduced overall survival after allogeneic stem cell transplantation. About 10% of patients showed spontaneous anti-SLLP humoral immunity. In addition, in vitro stimulation with SLLP1 could result in induction of antigen-specific T cells (63).

3.1.7. SPANXB

Its expression as well as induction of high titer immunoglobulin G (IgG) antibodies against it has been demonstrated in a subset of MM patients (64). It has been shown by microarray analysis to be expressed in a small percentage of MM patient samples and cell lines as well as MGUS and normal bone marrow plasma cells (36). SPANXB-derived peptides have been shown to induce CD8 + T cell response in MM patients as well as healthy donors (65).

3.1.8. SSX Genes

Several members of SSX (synovial sarcoma, X chromosome) genes including SSX1, SSX2, SSX4, SSX5, and SSX8 have been shown to be frequently expressed in MM cell lines. In addition, SSX6 are SSX7 shown to be less frequently expressed in such cell lines (30). These genes emerged as promising candidates for MM immunotherapy. Co-expression of SSX1, 2, 4, and 5 has been shown to be correlated with decreased survival (66). Although most of SSX genes are testis-restricted, some of them such as SSX4 have a less restricted pattern among normal tissues.

3.1.8.1. SSX1

It has been among the most frequent testis-restricted CTAs in both newly diagnosed and relapse MM patients. In relapse MM patients, the expression of SSX1 has been associated with shorter overall survival as well as shorter progression free survival (16). It has been shown by microarray analysis to be expressed in MM patient samples and cell lines but not in MGUS (36). Its mRNA expression has been shown to be significantly higher in advanced stage MM patients than in early stages (67).

3.1.8.2. SSX2

Its expression has been shown in both newly diagnosed MM cases and relapse ones with comparable frequencies (16). It has been shown to be expressed in 12% of all MM samples with a bone marrow plasma cell infiltration of more than 10% (14). It has been shown by microarray analysis to be expressed in a small percentage of MM patient samples and cell lines but not in MGUS (36). Another study has revealed a strong association between the expression of SSX2 and reduced survival (66).

3.1.8.3. SSX3

Its expression has been shown in both newly diagnosed MM cases and relapse ones with comparable frequencies (16). It has been shown by microarray analysis to be expressed in a small percentage of MM patient samples and cell lines but not in MGUS (36).

3.1.8.4. SSX4

It has been shown by microarray analysis to be expressed in MM patient samples and cell lines but not in MGUS (36). However, another study has shown its expression in a minority of healthy bone marrow samples (30). Its mRNA expression has been shown to be significantly higher in advanced stage patients than in early stages (67).

3.2. CTA Immunogenicity in MM Patients

The existence of blood-testis barrier has made testis an immune-privileged site so sperms in the testis do not elicit immune responses. Such barrier is made by tight junctions between Sertoli cells along the basolateral aspect and between capillary endothelial cells. Since spermatogenesis initiates at puberty, novel cell surface antigens are expressed after finishing the time for immune system to recognize self from non-self. In addition, antigen-presenting cells are barely seen within the seminiferous tubules and human leukocyte antigen (HLA) class I is not expressed on the surface of germ cells (21). For these reasons, testis specific antigens are not presented to the immune system and if such antigens are expressed in other tissues rather than testis, they can elicit immune responses. However, some CTAs are shown to be expressed in some normal tissues in a level which is not comparable with their high expression level in the testis and tumor cells. Such mRNA expression in normal tissues other than testis does not usually lead to protein expression and immunogenicity. Instead, high expression of CTAs on cancer cells as what has been demonstrated in MM cells can elicit immune responses. Humoral as well as cellular immune responses against CTAs have been demonstrated in MM patients. It has been shown that immune responses against CTAs are induced by alloSCT. Notably, in about half of patients who developed humoral responses, antibodies were specific for NY-ESO-1, a CTA which is not very frequently expressed in MM. This implies an important role for NY-ESO-1 in the immunology of MM. In addition, NY-ESO-1-specific CD4 + and CD8 + T-cell responses have been detected in a patient after alloSCT (30). Co-incubation of lymphocytes with MAGE-C1/CT7-transduced autologous myeloid DCs has resulted in an increase in INF-γ secretion by lymphocytes which implies that MAGE-C1/CT7 expression in MM cells could induce a T-cell immune response (54). In addition, MAGE-C1/CT7 has been shown to elicit spontaneous humoral responses in a subset of MM patients with all of them being in advance stages (68). Another study has shown CD8 + T cell activity against a number of CTAs including NY-ESO-1, LAGE-1 and some MAGE-A antigens in many MM patients (69). Collectively, these data show the ability of CTAs to elicit both humoral and cellular immune response in MM patients which implies the suitability of these antigens for immunotherapy of these patients.

3.3. Clinical Trials Using CTAs in MM

Frequent heterogeneous expression of CTAs within tumors and immune escape mechanisms of tumor cells imply that the use of different CTAs in a vaccine would be preferable (36). This strategy has been applied in some clinical trials. Such an approach would broaden the range of patients who benefit from a vaccine formulation. For instance, MAGE-C1/CT7, MAGE-A3/6 and LAGE-1 have been suggested as good candidates for immunotherapy, given that it has been shown that they collectively cover 85% of MM cases (34). A previous report has shown that immunization of a healthy donor with MAGE-A3 protein elicits strong antigen specific antibody, CD8 + and CD4 + T cell responses that can be transferred and expanded post-transplant in the recipient. Such an approach resulted in detectable MAGE-A3 specific immune responses until one year and clinical remission up to 2.5 years after transplant (70) (2007). Numerous clinical trials vaccinating MM patients with MAGE family and NY-ESO-1 are currently enrolling patients (71, 72). Table 2 shows a number of CTA-based clinical trials conducted in MM patients.

Table 2.

Selected CTA-Based Clinical Trials in Multiple Myeloma Patients

Immunological Response/ Trial StatusVaccine/AdjuvantNumber of PatientsPhaseStudy, yReference
Not Mentioned/ CompletedMAGE-A3 and NY-ESO-1 peptides in combo With DTPACE chemo and auto transplantation/ GM-CSF4 entered the study, 2 completedII/III2003-2004(73)
Humoral and cellular (CD8+) immune responses were induced./ completedMEL 200 tandem Tx (Tx1: auto, Tx2: syngeneic) and MAGE-3 recombinant protein/ ASO2B adjuvant1-2005(74)
Vaccine-specific T-cell responses were induced after transplantMAGE-A3 immunizations with Hiltonol® (Poly-ICLC) plus transfer of vaccine-primed autologous T cells followed by lenalidomide maintenance/ GM-CSF27II2010-2014(75, 76)
This study is ongoing, but not recruiting participantsrecombinant MAGE-A3 protein/AS1516I2011-2014(77)
Recruiting participantsAutologous T cells expressing a high affinity TCR specific for MAGE-A3/6 or NY-ESO-1 administered post ASCT26I/II2011-2031(78)
Recruiting participantsCT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells20I2013-2015(79)
Recruiting participantsEngineered Autologous T Cells Expressing an Affinity-enhanced TCR Specific for NY-ESO-1 and LAGE-110I/II2013-2031(80)
Not yet open for participant recruitmentTAA( NY-ESO-1, MAGEA4, PRAME, Survivin and SSX)-specific CTLs36I2014-2020(81)

3.4. Potential Side Effects Associated With Immunotherapy Modalities

Although immunotherapeutic approaches have been developed to lessen the side effects associated with conventional anti cancer modalities, they have been shown to cause adverse effects. For instance, although notable clinical responses were seen in a subset of patients treated with T cell receptor (TCR)-modified T cells redirected against two antigens including NY-ESO-1, on and off-target toxicity was associated with most of these clinical responses, and lethal complications have been detected in some patients (82). Of note, as some CTAs such as NY-ESO-1 have been shown to be expressed in normal stem cells, some potential side effects can be attributed to this expression pattern (9). In addition, materials used in the preparation of ex-vivo expanded T cells such as complex media, serum and cytokines, and genetic modification, can increase the risk for infusion reactions (83). However, DC based vaccination has been shown to be associated with low toxicity (84). Finally, administration of monoclonal antibodies can result in immune reactions such as acute anaphylaxis, serum sickness, the generation of antibodies as well as numerous adverse effects that are related to their specific targets (85). Consequently, attempts are focused on the minimization of immunotherapy associated side effects.

4. Conclusions

The frequent and high expression level of CTAs in MM patients shows that these antigens can be applied as cancer biomarkers as well as targets for immunotherapy in these patients. As down-regulation of CTA expression over time may restrict their potential application for immunotherapeutic approaches in cancers, it is necessary to evaluate their expression during the course of disease (14). Consequently, longitudinal analyses of CTA expression are of value. Among CTAs, the highest expressions in MM have been reported for MAGE-A, MAGE-C1 and NY-ESO-1 (47, 86). Therefore, future studies should focus on application of these antigens in clinical settings especially when considering the role of MAGE-C1 and MAGE-A3 in promoting the survival of myeloma cells.

The identification of CSCs in MM and the resistance of such cells to conventional and even novel therapies necessitate the search for new treatment modalities for elimination of such cells. Future studies should focus on the analysis of CTA expression in MM CSCs to find whether these antigens are special markers for these cells. CTA based immunotherapy has the possible advantage of targeting such cells within the populations of MM cells, thus preventing disease recurrence.

Acknowledgements

References

  • 1.

    Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010;21 Suppl 7:vii143-50. [PubMed ID: 20943607]. https://doi.org/10.1093/annonc/mdq370.

  • 2.

    Dimopoulos MA, Kastritis E, Anagnostopoulos A. Hematological malignancies: myeloma. Ann Oncol. 2006;17 Suppl 10:x137-43. [PubMed ID: 17018714]. https://doi.org/10.1093/annonc/mdl251.

  • 3.

    Boyle EM, Davies FE, Leleu X, Morgan GJ. Understanding the multiple biological aspects leading to myeloma. Haematologica. 2014;99(4):605-12. [PubMed ID: 24688108]. https://doi.org/10.3324/haematol.2013.097907.

  • 4.

    Huff CA, Matsui W. Multiple myeloma cancer stem cells. J Clin Oncol. 2008;26(17):2895-900. [PubMed ID: 18539970]. https://doi.org/10.1200/JCO.2007.15.8428.

  • 5.

    Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516-20. [PubMed ID: 17975015]. https://doi.org/10.1182/blood-2007-10-116129.

  • 6.

    Brennan SK, Matsui W. Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl). 2009;87(11):1079-85. [PubMed ID: 19760278]. https://doi.org/10.1007/s00109-009-0531-7.

  • 7.

    Tabarestani S, Ghafouri-Fard S. Cancer stem cells and response to therapy. Asian Pac J Cancer Prev. 2012;13(12):5951-8. [PubMed ID: 23464384].

  • 8.

    Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190-7. [PubMed ID: 18172311]. https://doi.org/10.1158/0008-5472.CAN-07-3096.

  • 9.

    Ghafouri-Fard S. Expression of cancer-testis antigens in stem cells: is it a potential drawback or an advantage in cancer immunotherapy. Asian Pac J Cancer Prev. 2015;16(7):3079-81. [PubMed ID: 25854409].

  • 10.

    Costello RT, Rey J, Fauriat C, Gastaut JA, Olive D. New approaches in the immunotherapy of haematological malignancies. Eur J Haematol. 2003;70(5):333-45. [PubMed ID: 12694173].

  • 11.

    Klippel ZK, Chou J, Towlerton AM, Voong LN, Robbins P, Bensinger WI, et al. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther. 2014;21(3):337-42. [PubMed ID: 24451117]. https://doi.org/10.1038/gt.2013.87.

  • 12.

    Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol. 2012. 196063. [PubMed ID: 22567028]. https://doi.org/10.1155/2012/196063.

  • 13.

    Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013;121(15):2975-87. [PubMed ID: 23321256]. https://doi.org/10.1182/blood-2012-08-448548.

  • 14.

    Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res. 2009;15(4):1343-52. [PubMed ID: 19190130]. https://doi.org/10.1158/1078-0432.CCR-08-0989.

  • 15.

    Locke FL, Nishihori T, Alsina M, Kharfan-Dabaja MA. Immunotherapy strategies for multiple myeloma: the present and the future. Immunotherapy. 2013;5(9):1005-20. [PubMed ID: 23998734]. https://doi.org/10.2217/imt.13.97.

  • 16.

    van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, et al. Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica. 2011;96(11):1662-9. [PubMed ID: 21791470]. https://doi.org/10.3324/haematol.2010.037978.

  • 17.

    de Carvalho F, Vettore AL, Colleoni GW. Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. Clin Dev Immunol. 2012;2012:257695. [PubMed ID: 22481966]. https://doi.org/10.1155/2012/257695.

  • 18.

    Bae J, Munshi NC, Anderson KC. Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014;28(5):927-43. [PubMed ID: 25212890]. https://doi.org/10.1016/j.hoc.2014.07.002.

  • 19.

    Dianatpour M, Mehdipour P, Nayernia K, Mobasheri MB, Ghafouri-Fard S, Savad S, et al. Expression of Testis Specific Genes TSGA10, TEX101 and ODF3 in Breast Cancer. Iran Red Crescent Med J. 2012;14(11):722-6. [PubMed ID: 23396665]. https://doi.org/10.5812/ircmj.3611.

  • 20.

    Ghafouri-Fard S, Abbasi A, Moslehi H, Faramarzi N, Taba Taba Vakili S, Mobasheri MB, et al. Elevated expression levels of testis-specific genes TEX101 and SPATA19 in basal cell carcinoma and their correlation with clinical and pathological features. Br J Dermatol. 2010;162(4):772-9. [PubMed ID: 19886887]. https://doi.org/10.1111/j.1365-2133.2009.09568.x.

  • 21.

    Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med. 2009;12(4):395-404. [PubMed ID: 19566358].

  • 22.

    Ghafouri-Fard S, Modarressi MH. Expression of cancer-testis genes in brain tumors: implications for cancer immunotherapy. Immunotherapy. 2012;4(1):59-75. [PubMed ID: 22150001]. https://doi.org/10.2217/imt.11.145.

  • 23.

    Seifi-Alan M, Shamsi R, Ghafouri-Fard S, Mirfakhraie R, Zare-Abdollahi D, Movafagh A, et al. Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev. 2014;14(11):6625-9. [PubMed ID: 24377578].

  • 24.

    Ghafouri-Fard S, Modarressi MH, Yazarloo F. Expression of testis-specific genes, TEX101 and ODF4, in chronic myeloid leukemia and evaluation of TEX101 immunogenicity. Ann Saudi Med. 2012;32(3):256-61. [PubMed ID: 22588436]. https://doi.org/10.5144/0256-4947.2012.256.

  • 25.

    Ghafouri-Fard S, Nekoohesh L, Motevaseli E. Bladder cancer biomarkers: review and update. Asian Pac J Cancer Prev. 2014;15(6):2395-403. [PubMed ID: 24761840].

  • 26.

    Ghafouri-Fard S, Ghafouri-Fard S. siRNA and cancer immunotherapy. Immunotherapy. 2012;4(9):907-17. [PubMed ID: 23046235]. https://doi.org/10.2217/imt.12.87.

  • 27.

    Ghafouri-Fard S, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S. Cancer-testis genes as candidates for immunotherapy in breast cancer. Immunotherapy. 2014;6(2):165-79. [PubMed ID: 24491090]. https://doi.org/10.2217/imt.13.165.

  • 28.

    Ghafouri-Fard S, Rezazadeh F, Zare-Abdollahi D, Omrani MD, Movafagh A. Are so-called cancer-testis genes expressed only in testis? Asian Pac J Cancer Prev. 2014;15(18):7703-5. [PubMed ID: 25292049].

  • 29.

    Hofmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, Chua R, et al. Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci U S A. 2008;105(51):20422-7. [PubMed ID: 19088187]. https://doi.org/10.1073/pnas.0810777105.

  • 30.

    Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007;109(3):1103-12. [PubMed ID: 17023585]. https://doi.org/10.1182/blood-2006-04-014480.

  • 31.

    Evans JP. Fertilin beta and other ADAMs as integrin ligands: insights into cell adhesion and fertilization. Bioessays. 2001;23(7):628-39. [PubMed ID: 11462216]. https://doi.org/10.1002/bies.1088.

  • 32.

    Turner RM, Musse MP, Mandal A, Klotz K, Jayes FC, Herr JC, et al. Molecular genetic analysis of two human sperm fibrous sheath proteins, AKAP4 and AKAP3, in men with dysplasia of the fibrous sheath. J Androl. 2001;22(2):302-15. [PubMed ID: 11229805].

  • 33.

    Chiriva-Internati M, Ferrari R, Yu Y, Hamrick C, Gagliano N, Grizzi F, et al. AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol. 2008;140(4):465-8. [PubMed ID: 18217892]. https://doi.org/10.1111/j.1365-2141.2007.06940.x.

  • 34.

    Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun. 2008;8:2. [PubMed ID: 18237105].

  • 35.

    van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999;94(4):1156-64. [PubMed ID: 10438702].

  • 36.

    Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol. 2007;178(5):3307-15. [PubMed ID: 17312182].

  • 37.

    Hayama S, Daigo Y, Kato T, Ishikawa N, Yamabuki T, Miyamoto M, et al. Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res. 2006;66(21):10339-48. [PubMed ID: 17079454]. https://doi.org/10.1158/0008-5472.CAN-06-2137.

  • 38.

    Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, et al. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet. 2006;38(6):674-81. [PubMed ID: 16682973]. https://doi.org/10.1038/ng1786.

  • 39.

    Zhao WM, Seki A, Fang G. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis. Mol Biol Cell. 2006;17(9):3881-96. [PubMed ID: 16790497]. https://doi.org/10.1091/mbc.E06-01-0015.

  • 40.

    Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D. Prognostic factors associated with response in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol. 2003.

  • 41.

    Liggins AP, Lim SH, Soilleux EJ, Pulford K, Banham AH. A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies. Cancer Immun. 2010;10:8. [PubMed ID: 20726502].

  • 42.

    Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574-82. [PubMed ID: 21173094]. https://doi.org/10.3324/haematol.2010.033456.

  • 43.

    Condomines M, Hose D, Reme T, Requirand G, Hundemer M, Schoenhals M, et al. Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol. 2009;183(2):832-40. [PubMed ID: 19542363]. https://doi.org/10.4049/jimmunol.0803298.

  • 44.

    Tinguely M, Jenni B, Knights A, Lopes B, Korol D, Rousson V, et al. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci. 2008;99(4):720-5. [PubMed ID: 18307538]. https://doi.org/10.1111/j.1349-7006.2008.00738.x.

  • 45.

    clinicaltrials.gov. Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma. Available from: http://clinicaltrials.gov/show/NCT00090493.

  • 46.

    Nuber N, Curioni-Fontecedro A, Matter C, Soldini D, Tiercy JM, von Boehmer L, et al. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci U S A. 2010;107(34):15187-92. [PubMed ID: 20696919]. https://doi.org/10.1073/pnas.1002155107.

  • 47.

    Lim SH, Austin S, Owen-Jones E, Robinson L. Expression of testicular genes in haematological malignancies. Br J Cancer. 1999;81(7):1162-4. [PubMed ID: 10584877]. https://doi.org/10.1038/sj.bjc.6690824.

  • 48.

    Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer. 1998;76(6):903-8. [PubMed ID: 9626360].

  • 49.

    Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 2001;61(14):5544-51. [PubMed ID: 11454705].

  • 50.

    Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M, et al. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol. 2007;127(2):267-75. [PubMed ID: 16960553]. https://doi.org/10.1038/sj.jid.5700548.

  • 51.

    van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643-7. [PubMed ID: 1840703].

  • 52.

    Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010;95(5):785-93. [PubMed ID: 20015885]. https://doi.org/10.3324/haematol.2009.014464.

  • 53.

    Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11(22):8055-62. [PubMed ID: 16299236]. https://doi.org/10.1158/1078-0432.CCR-05-1203.

  • 54.

    Cho HJ, Caballero OL, Gnjatic S, Andrade VC, Colleoni GW, Vettore AL, et al. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun. 2006;6:12. [PubMed ID: 17137291].

  • 55.

    Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003;3:9. [PubMed ID: 12875607].

  • 56.

    Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106(1):167-74. [PubMed ID: 15761016]. https://doi.org/10.1182/blood-2004-12-4931.

  • 57.

    de Carvalho F, Costa ET, Camargo AA, Gregorio JC, Masotti C, Andrade VC, et al. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. PLoS One. 2011;6(11). e27707. [PubMed ID: 22110734]. https://doi.org/10.1371/journal.pone.0027707.

  • 58.

    Pabst C, Zustin J, Jacobsen F, Luetkens T, Kroger N, Schilling G, et al. Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol. 2010;89(2):175-81. [PubMed ID: 20621094]. https://doi.org/10.1016/j.yexmp.2010.06.011.

  • 59.

    Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, Reyner K, et al. Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun. 2010;10:4. [PubMed ID: 20108890].

  • 60.

    Anderson LJ, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR. Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother. 2011;60(7):985-97. [PubMed ID: 21461886]. https://doi.org/10.1007/s00262-011-1009-3.

  • 61.

    van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105(10):3939-44. [PubMed ID: 15671442]. https://doi.org/10.1182/blood-2004-09-3707.

  • 62.

    Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, et al. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011;34(6):490-9. [PubMed ID: 21654522]. https://doi.org/10.1097/CJI.0b013e31821ca76f.

  • 63.

    Yousef S, Heise J, Lajmi N, Bartels K, Kroger N, Luetkens T, et al. Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. J Transl Med. 2015;13:197. [PubMed ID: 26088750]. https://doi.org/10.1186/s12967-015-0562-5.

  • 64.

    Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim SH. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood. 2003;101(3):955-60. [PubMed ID: 12393489]. https://doi.org/10.1182/blood-2002-06-1930.

  • 65.

    Frank C, Hundemer M, Ho AD, Goldschmidt H, Witzens-Harig M. Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma. 2008;49(4):779-85. [PubMed ID: 18398747]. https://doi.org/10.1080/10428190801911688.

  • 66.

    Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, et al. SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs. J Immunother. 2005;28(6):564-75. [PubMed ID: 16224274].

  • 67.

    He L, Ji JN, Liu SQ, Xue E, Liang Q, Ma Z. Expression of cancer-testis antigen in multiple myeloma. J Huazhong Univ Sci Technolog Med Sci. 2014;34(2):181-5. [PubMed ID: 24710929]. https://doi.org/10.1007/s11596-014-1255-7.

  • 68.

    Fontecedro AC, Knights A, Tinguely M, Rosa O, Lopes B, Moch H. Expression and immunogenicity of the cancer-testis antigen CT7 (MAGE-C1) in patients with multiple myeloma. J Clin Oncol (ASCO Annual Meeting). 2007;25:8112.

  • 69.

    Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G, et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood. 2005;106(13):4217-24. [PubMed ID: 16144804]. https://doi.org/10.1182/blood-2005-02-0563.

  • 70.

    Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007;30(8):847-54. [PubMed ID: 18049337]. https://doi.org/10.1097/CJI.0b013e318158fcff.

  • 71.

    Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015;7(6):683-704. [PubMed ID: 26100270]. https://doi.org/10.2217/imt.15.29.

  • 72.

    Esfandiary A, Ghafouri-Fard S. New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. Immunotherapy. 2015;7(4):411-39. [PubMed ID: 25917631]. https://doi.org/10.2217/imt.15.3.

  • 73.

    Sahota SS, Goonewardena CM, Cooper CD, Liggins AP, Ait-Tahar K, Zojer N, et al. PASD1 is a potential multiple myeloma-associated antigen. Blood. 2006;108(12):3953-5. [PubMed ID: 17114574]. https://doi.org/10.1182/blood-2006-04-014621.

  • 74.

    Gnjatic S, Szmania S, Moreno A, Cottler-Fox M, Shaughnessy J, Barlogie B, editors. Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient. ASH Annual Meeting Abstracts. 2005. 2197 p.

  • 75.

    Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res. 2014;20(5):1355-65. [PubMed ID: 24520093]. https://doi.org/10.1158/1078-0432.CCR-13-2817.

  • 76.

    clinicaltrials.gov. Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma. Available from: https://clinicaltrials.gov/show/NCT01245673.

  • 77.

    clinicaltrials.gov. MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

  • 78.

    clinicaltrials.gov. Redirected Auto T Cells for Advanced Myeloma.

  • 79.

    clinicaltrials.gov. CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

  • 80.

    clinicaltrials.gov. CT Antigen TCR-Engineered T Cells for Myeloma.

  • 81.

    clinicaltrials.gov. Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (TACTAM).

  • 82.

    Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther. 2013;20(11):1029-32. [PubMed ID: 23804078]. https://doi.org/10.1038/gt.2013.34.

  • 83.

    Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010;12(6):743-9. [PubMed ID: 20429793]. https://doi.org/10.3109/14653241003709686.

  • 84.

    Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257-67. [PubMed ID: 24872109]. https://doi.org/10.1016/S1470-2045(13)70585-0.

  • 85.

    Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325-38. [PubMed ID: 20305665]. https://doi.org/10.1038/nrd3003.

  • 86.

    Meklat F, Li Z, Wang Z, Zhang Y, Zhang J, Jewell A, et al. Cancer-testis antigens in haematological malignancies. Br J Haematol. 2007;136(6):769-76. [PubMed ID: 17223912]. https://doi.org/10.1111/j.1365-2141.2006.06484.x.